|1.||Avila, Jesús: 19 articles (01/2014 - 05/2003)|
|2.||Hernández, Félix: 15 articles (09/2015 - 08/2003)|
|3.||Lucas, José J: 13 articles (09/2015 - 01/2004)|
|4.||Woodgett, James R: 11 articles (09/2015 - 04/2003)|
|5.||Eldar-Finkelman, Hagit: 10 articles (09/2013 - 03/2002)|
|6.||Medina, Miguel: 9 articles (02/2014 - 09/2007)|
|7.||Martinez, Ana: 8 articles (03/2014 - 07/2002)|
|8.||Wang, Jian-Zhi: 7 articles (01/2013 - 05/2005)|
|9.||Koh, Seong-Ho: 7 articles (10/2012 - 10/2003)|
|10.||Patel, Satish: 7 articles (03/2011 - 09/2004)|
|1.||Alzheimer Disease (Alzheimer's Disease)
09/01/2010 - "Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease."
01/01/2005 - "The study demonstrated that overactivation of GSK-3 induced hyperphosphorylation of neurofilament and suggested that in vitro overactivation of GSK-3 resulted in neurofilament hyperphosphorylation and this may be the underlying mechanism for Alzheimer's disease."
01/01/2016 - "Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease."
05/01/2015 - "When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compound showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396. "
01/01/2014 - "Furthermore, GSK-3 dysfunction has been linked to a number of pathologies, including Alzheimer's disease (AD). "
|2.||Schizophrenia (Dementia Praecox)
06/01/2004 - "This may indicate that investigation of the genetics of GSK-3 beta regulation holds promise for understanding some of the biochemical underpinnings of schizophrenia."
04/01/2008 - "Previous studies have suggested that GSK-3 beta might act as a potential candidate locus for schizophrenia susceptibility. "
01/01/2005 - "Taken together, these studies suggest that low GSK-3 in postmortem brain of schizophrenic patients is a late consequence of perinatal neurodevelopmental insult in schizophrenia. "
06/01/2003 - "The present study aimed to evaluate the possible involvement of neuroleptic treatment in the decrease of GSK-3 in schizophrenia. "
09/01/2014 - "A link with schizophrenia is suggested by the antipsychotic drug-induced GSK-3 regulation and by the involvement of the Akt/GSK-3 pathway in dopaminergic neurotransmission. "
08/19/2011 - "Beta isoform-specific inhibition of GSK-3 by dominant negative GSK-3β in transgenic mice (Tg-DnGSK-3β) or in heterozygous GSK-3β knock-out mice (GSK-3β+/-) significantly increased, whereas activation of GSK-3β in constitutively active GSK-3β knock-in mice (βKI) significantly decreased, myocardial ischemic injury after prolonged ischemia. "
08/01/2008 - "Moreover, direct pharmacological inhibition of GSK-3 catalytic activity with structurally diverse inhibitors before or after ischemia failed to recapitulate conditioning protection. "
07/01/2008 - "However, expression of GSK-3 beta in transient intrauterine ischemia group increased (P < 0.05). "
01/01/2008 - "sFRP-1 overexpression in endothelium specifically reversed the inactivation of GSK-3 beta and increased neovascularization in ischemia-induced angiogenesis in mouse hindlimb. "
07/11/2008 - "These protective effects were associated with reductions of TUNEL-positive cells, neutrophil infiltration, glucose levels after ischemia, and GSK-3 enzyme activity. "
12/11/2015 - "Tumor Suppressor Lzap Suppresses Wnt/β-Catenin Signaling to Promote Zebrafish Embryonic Ventral Cell Fates via the Suppression of Inhibitory Phosphorylation of Glycogen Synthase Kinase 3."
12/01/2015 - "Glycogen synthase kinase 3 in Wnt signaling pathway and cancer."
09/01/2015 - "Multiple inhibitors to EGFR, PI3K, mTOR, GSK-3, Raf, MEK and hedgehog (HH) have been developed and are being evaluated in various cancers. "
08/27/2015 - "GSK-3 inhibitors may be useful in targeting mTORC1 and lysosomal acidification for cancer therapy. "
08/27/2015 - "Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth."
10/01/2013 - "GSK-3 inhibition did not affect weight but improved insulin resistance, also on cellular level. "
08/01/1999 - "Taken together, our studies suggest an unsuspected link between increased GSK-3 activity and development of insulin resistance and type 2 diabetes in fat tissue of C57BL/6J mice, and implicate GSK-3 as a potential factor contributing to susceptibility of C57BL/6J mice to diet-induced diabetes."
09/01/2010 - "The evidence to date supports an important role of GSK-3 dysfunction in the multifactorial etiology of insulin resistance in skeletal muscle. "
06/01/2008 - "The high-fat-fed lean Zucker rat: a spontaneous isocaloric model of fat-induced insulin resistance associated with muscle GSK-3 overactivity."
09/01/2007 - "Recognizing GSK-3 and Hsps in the pathogenesis of insulin resistance, the central common feature of the metabolic syndrome, and type 2 diabetes will expand our understanding of the disease, offering new therapeutic options."
|5.||Glycogen Synthase (Synthase I)
|6.||Proteins (Proteins, Gene)
|7.||tau Proteins (tau Protein)
|9.||Valproic Acid (Valproate, Semisodium)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)